Sugi Predict

Sugi Predict / Compounds / Lithium

Lithium

Lithium

SCHEMBL7189947

Cc1cc(C(C)(C)C)cc(C)c1C(=O)Pc1ccc(OCc2ccccc2)cc1OCc1ccccc1.[Li]

nearest known ligand 0.46

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NR4A2 P43354 2/20 0.46
▸ NR4A1 P22736 1/20 0.46
▸ NR4A3 Q92570 1/20 0.46
▸ MAOB P27338 5/20 0.44
▸ RXRA P19793 4/20 0.44
▸ RXRB P28702 4/20 0.44
▸ MRGPRX4 Q96LA9 1/20 0.43
▸ CASP3 P42574 2/20 0.43
▸ SENP8 Q96LD8 2/20 0.43
▸ SENP7 Q9BQF6 2/20 0.43
▸ SENP6 Q9GZR1 2/20 0.43
▸ FFAR4 Q5NUL3 1/20 0.41
▸ RAB9A P51151 2/20 0.41
▸ L3MBTL1 Q9Y468 2/20 0.41
▸ PKM P14618 1/20 0.40
▸ NPC1 O15118 1/20 0.40
▸ MAOA P21397 1/20 0.40
▸ TDP1 Q9NUW8 1/20 0.40
▸ RXRG P48443 3/20 0.40
▸ FFAR1 O14842 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7189943 0.98 NR4A2 (0.46) NR4A2NR4A1NR4A3MAOBRXRA
Lithium SCHEMBL7181073 0.90 MAOB (0.46) MAOBRXRARXRBCASP3SENP8
SCHEMBL7188222 0.89 NR4A2 (0.47) NR4A2NR4A1NR4A3MAOBRXRA
Lithium SCHEMBL7177776 0.89 MAOB (0.48) NR4A2MAOBRXRARXRBCASP3
SCHEMBL7181059 0.88 MAOB (0.46) MAOBRXRARXRBCASP3SENP8
SCHEMBL7177769 0.87 MAOB (0.48) NR4A2MAOBRXRARXRBCASP3
Lithium SCHEMBL7187088 0.86 MAOB (0.44) MAOBRXRARXRBCASP3SENP8
SCHEMBL7190536 0.85 MRGPRX4 (0.45) NR4A2NR4A1NR4A3MAOBRXRA
SCHEMBL7187077 0.84 MAOB (0.44) MAOBRXRARXRBCASP3SENP8
Lithium SCHEMBL7178017 0.83 KDM4E (0.42) MAOB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6579663-B2 Chemical intermediates such as lithium 2,6-dimethylbenzoyl phenylphosphine for preparation of acylphosphines, acylphosphine oxides or acylphosphine sulfides CIBA SPECIALTY CHEMICALS CORPORATION 2003-06-17 — — US disclosed
US-20020107413-A1 Organometallic monoacylarylphosphines WOLF JEAN-PIERRE (CH) 2002-08-08 — — US disclosed
US-6399805-B2 SUCH AS LITHIUM 2,6-DIMETHYLBENZOYLPHENYLPHOSPHINE, USE AS PHOTOINITIATORS IN PHOTOCURABLE COMPOSITIONS SUCH AS FOR PHOTOGRAPHIC PRODUCTION OF RELIEF IMAGES CIBA SPECIALTY CHEMICALS CORPORATION 2002-06-04 — — US disclosed
US-20010031898-A1 Organometallic monoacylarylphosphines CIBA SPECIALTY CHEMICALS CORP. 2001-10-18 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020107413-A1 Organometallic monoacylarylphosphines CBR1, NAF1, DHCR24 NR4A2 1314/4885NR4A1 219/4885NR4A3 901/4885
US-20010031898-A1 Organometallic monoacylarylphosphines NAF1, DHCR24, CBR1 NR4A2 1389/4885NR4A1 356/4885NR4A3 871/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.